- Home
- / Biocon
Biocon
Stock Price
₹327
2024-10-29
Market Capitalization
₹386 B
2024-10-29
Revenue
₹150.5 B
FY, 2025
Biocon Summary
Company Summary
- Overview
- Biocon is a company that develops and manufactures biopharmaceutical products. It offers aminocaproic acids, biosimilar pipelines, spanning insulins, monoclonal antibodies, and other products for diabetes, oncology, and immunology therapeutic areas. The company caters to the pharmaceutical, biotechnology, chemical, and agrochemical industries.
- Type
- Public
- Status
- Active
- Founded
- 1978
- HQ
- Bengaluru, IN | view all locations
- Website
- https://www.biocon.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kiran Mazumdar-Shaw, Executive Chairperson
Ravi Mazumdar, Non-Executive Director
Shreehas P. Tambe, CEO & Managing Director, Biocon Biologics Limited
LocationsView all
11 locations detected
Bengaluru, KA HQ
India
20th KM, Hosur Road
Cambridge, MA
United States
245 Main St 2nd floor
Bengaluru, KA
India
Biocon House, Semicon Park, Electronics City, Phase – II, Hosur Road
Nanakramguda, TS
India
Plot No. 31, Road No. 1, Financial District
Dublin, D
Ireland
9 Clare St
Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur
Malaysia
Level 7, Menara Milenium Jalan Damanlela, Pusat Bandar Damansara, Damansara Heights
Biocon Financials
Summary Financials
- Revenue (Q3, 2026)
- ₹41.2B
- Gross profit (Q3, 2026)
- ₹29.5B
- Net income (Q3, 2026)
- (₹518.0M)
- Cash (FY, 2026)
- ₹31.9B
- EBIT (Q3, 2026)
- ₹1.4B
- Enterprise value
- $508.4B